drugset / Trial / NCT05002517
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab
RandomizedParallel-groupTriple-blindTreatment
Summary
Randomized, open, single-center, controlled clinical trial, with 2 treatment arms that seeks to demonstrate the effectiveness of tocilizumab against systemic corticosteroids, both treatments added to supportive treatment in patients admitted for COVID-19 with bilateral pneumonia and poor evolution
Timeline
- Start
- 2020-09-03
- Primary completion
- 2021-07-31
- Completion
- 2021-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methylprednisolone | Other / unclassified | 250 mg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 600 mg | Intravenous |